CPH 82
Alternative Names: ReumaconLatest Information Update: 04 Nov 2017
At a glance
- Originator Analytecon; Conpharm
- Developer Meda
- Class Antirheumatics; Glycosides; Lignans
- Mechanism of Action Microtubule protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
- Discontinued Alzheimer's disease; Amyloidosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Rheumatoid-arthritis in Sweden (PO, Capsule)
- 05 Aug 2016 Meda has been acquired by Mylan
- 30 Jun 2009 CPH 82 is still in active development for rheumatoid arthritis